Naproxen
- Generic Name
- Naproxen
- Brand Names
- Aleve, Aleve PM, Aleve-D, Anaprox, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo
- Drug Type
- Small Molecule
- Chemical Formula
- C14H14O3
- CAS Number
- 22204-53-1
- Unique Ingredient Identifier
- 57Y76R9ATQ
- Background
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, nap...
- Indication
Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain. Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskelet...
- Associated Conditions
- Acute Gouty Arthritis, Acute Migraine, Ankylosing Spondylitis (AS), Back pain, Bursitis, Extra-Articular Rheumatism, Fever, Flu caused by Influenza, Headache, Juvenile Idiopathic Arthritis (JIA), Menstrual Distress (Dysmenorrhea), Migraine, Muscle Spasms, Nasal Congestion, Osteoarthritis (OA), Pain, Post Traumatic Pain, Postoperative pain, Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Seasonal Allergic Rhinitis, Sinusitis, Tendinitis, Toothache, Articular inflammation
- Associated Therapies
- -
Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT02116790
A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 89
- Registration Number
- NCT02108548
- Locations
- 🇬🇧
Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom
Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 81
- Registration Number
- NCT02052908
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 82
- Registration Number
- NCT02013427
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Effect of Metamizole (Dipyrone) on Renal Function in Salt-depleted Healthy Subjects
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 15
- Registration Number
- NCT01995006
- Locations
- 🇨🇭
Phase I Research Unit, University Hospital, Basel, Switzerland
Effect of L-dopa In Subacute Back Pain Population
- Conditions
- Interventions
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 72
- Registration Number
- NCT01951105
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 251
- Registration Number
- NCT01939002
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
- Conditions
- Interventions
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Ache Laboratorios Farmaceuticos S.A.
- Registration Number
- NCT01726920
NOLAN: Naproxen or Loratadine and Neulasta
- Conditions
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 600
- Registration Number
- NCT01712009
- Locations
- 🇺🇸
Research Site, Weston, Wisconsin, United States
Low Level Laser Therapy Versus Pharmacotherapy in in Improving Masticatory Muscle Pain
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Shahid Beheshti University
- Target Recruit Count
- 40
- Registration Number
- NCT01659372
- Locations
- 🇮🇷
Shahid Beheshti University, Tehran, Iran, Islamic Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.